Abstract
The endothelin axis (ET axis), comprising the three peptides endothelin (ET)-1, -2, -3 and their receptors ETAR and ETBR, is expressed in various cells and tissues. The biologically active ET-1 is formed by endothelin-converting enzyme (ECE) from inactive big-ET-1. ET-1 has emerged as an important peptide in a host of biological functions, including development, cellular proliferation, apoptosis and angiogenesis, thereby playing an important physiological and pathophysiological role. As these effects are mediated by ETAR, activation of ETBR prevents apoptosis, inhibits ECE expression and mediates the clearance of ET-1. Emerging data indicate that the ET axis is involved in tumourigenesis and tumour progression of various cancers. Expression of the ET axis has been demonstrated in a wide range of human tumours. Since most data have been reported for female malignancies, this review will focus on the role of the ET axis in cancers of the ovary, the cervix and the breast. In ovarian cancer, activation of ETAR by ET-1 is a key mechanism in the cellular signalling network promoting cancer growth and progression. Similar effects have been shown for cervical and endometrial cancer. In breast cancer, ET-1 via ETAR promotes proliferation and invasion, mediates bone metastases and predicts unfavourable response to chemotherapy. The outstanding role of ET-1 and ETAR in carcinogenesis and tumour progression has led to an extensive search for interfering agents, resulting in the development of selective ETAR antagonists on the one hand and inhibitors of the endothelinconverting enzyme (ECE) on the other. Targeting the ET axis via ETAR or ECE blockade seems to be a promising approach in the treatment of female malignancies.
Keywords: ET axis, ETAR, atrasentan, ZD4054, breast cancer
Current Vascular Pharmacology
Title: The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Volume: 5 Issue: 3
Author(s): Martin Smollich and Pia Wulfing
Affiliation:
Keywords: ET axis, ETAR, atrasentan, ZD4054, breast cancer
Abstract: The endothelin axis (ET axis), comprising the three peptides endothelin (ET)-1, -2, -3 and their receptors ETAR and ETBR, is expressed in various cells and tissues. The biologically active ET-1 is formed by endothelin-converting enzyme (ECE) from inactive big-ET-1. ET-1 has emerged as an important peptide in a host of biological functions, including development, cellular proliferation, apoptosis and angiogenesis, thereby playing an important physiological and pathophysiological role. As these effects are mediated by ETAR, activation of ETBR prevents apoptosis, inhibits ECE expression and mediates the clearance of ET-1. Emerging data indicate that the ET axis is involved in tumourigenesis and tumour progression of various cancers. Expression of the ET axis has been demonstrated in a wide range of human tumours. Since most data have been reported for female malignancies, this review will focus on the role of the ET axis in cancers of the ovary, the cervix and the breast. In ovarian cancer, activation of ETAR by ET-1 is a key mechanism in the cellular signalling network promoting cancer growth and progression. Similar effects have been shown for cervical and endometrial cancer. In breast cancer, ET-1 via ETAR promotes proliferation and invasion, mediates bone metastases and predicts unfavourable response to chemotherapy. The outstanding role of ET-1 and ETAR in carcinogenesis and tumour progression has led to an extensive search for interfering agents, resulting in the development of selective ETAR antagonists on the one hand and inhibitors of the endothelinconverting enzyme (ECE) on the other. Targeting the ET axis via ETAR or ECE blockade seems to be a promising approach in the treatment of female malignancies.
Export Options
About this article
Cite this article as:
Martin Smollich and Pia Wulfing , The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies, Current Vascular Pharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157016107781024082
DOI https://dx.doi.org/10.2174/157016107781024082 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Oncostatin M: Potential Implications for Malignancy and Metabolism
Current Pharmaceutical Design ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK)
Current Pharmaceutical Design The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Technetium-99m-based Radiopharmaceuticals in Sentinel Lymph Node Biopsy: Gynecologic Oncology Perspective
Current Pharmaceutical Design Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Fertility Drugs and Ovarian Cancer
Current Cancer Drug Targets Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of Phytoestrogens and Derivatives: An Update of the Promising Perspectives in the Prevention of Postmenopausal Diseases
Mini-Reviews in Medicinal Chemistry Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling
Current Drug Discovery Technologies Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Current Drug Metabolism Bioinformatics Analysis Predicts hsa_circ_0026337/miR-197-3p as a Potential Oncogenic ceRNA Network for Non-Small Cell Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Colorectal Cancer – Increased Multidimensional Understanding of the Molecular Genesis
Current Cancer Therapy Reviews